Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice [0.03%]
口服与注射型疾病修正疗法治疗多发性硬化症的疗效和耐受性临床实践的差异
Erin E Longbrake,Anne H Cross,Amber Salter
Erin E Longbrake
Background: The advent of oral disease-modifying therapies fundamentally changed the treatment of multiple sclerosis. Nevertheless, impressions of their relative efficacy and tolerability are primarily founded on expert o...
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance [0.03%]
富马酸二甲酯相关淋巴细胞减少的风险因素及临床意义
Erin E Longbrake,Robert T Naismith,Becky J Parks et al.
Erin E Longbrake et al.
Background: Dimethyl fumarate (DMF), a disease-modifying therapy for multiple sclerosis (MS), causes lymphopenia in a fraction of patients. The clinical significance of this is unknown. Several cases of progressive multif...
Multiple sclerosis greatly impacts family members/partners: Evidence using the Family Reported Outcome Measure (FROM-16) [0.03%]
家庭报告结果测量表(FROM-16)显示多发性硬化症对家庭成员/伴侣影响巨大
Background: Multiple sclerosis (MS) may have a major impact on the physical, social and psychological wellbeing of people with multiple sclerosis (pwMS) and their family members/partners. ...